Similarly, the combination of PD-1/PD-L1 inhibitors with chemotherapy showed a better PFS compared to chemotherapy alone for ESCC patients (I2 = 11%, HR: 0.62, 95% CI: 0.58-0.67). Here, CD274 is linked to esophageal squamous cell carcinoma.